Osvalgo Pontiggia - Publications

Affiliations: 
2006-2010 Instituto de Oncología "Angel H. Roffo" 

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Raffo D, Pontiggia O, Bal de Kier Joffé E, Simian M. Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells. Oncology Reports. 33: 439-47. PMID 25338647 DOI: 10.3892/Or.2014.3558  0.793
2013 Raffo D, Berardi DE, Pontiggia O, Todaro L, de Kier Joffé EB, Simian M. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Research and Treatment. 142: 537-48. PMID 24258256 DOI: 10.1007/S10549-013-2760-2  0.781
2012 Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffé EB, Simian M. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Research and Treatment. 133: 459-71. PMID 21935603 DOI: 10.1007/S10549-011-1766-X  0.757
2011 Perona M, Pontiggia O, Carpano M, Thomasz L, Thorp S, Pozzi E, Simian M, Kahl S, Juvenal G, Pisarev M, Dagrosa A. In vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 69: 1732-6. PMID 21530283 DOI: 10.1016/j.apradiso.2011.03.044  0.642
2011 Raffo D, Pontiggia O, Simian M. Role of MMPs in metastatic dissemination: implications for therapeutic advances. Current Pharmaceutical Biotechnology. 12: 1937-47. PMID 21470127 DOI: 10.2174/138920111798377085  0.731
2011 Sampayo R, Pontiggia O, Raffo D, Joffe EBdK, Simian M. Abstract 545: Laminin induces tamoxifen resistance through alfa 6 integrin in breast cancer cells Cancer Research. 71: 545-545. DOI: 10.1158/1538-7445.Am2011-545  0.752
2010 Pontiggia R, Pontiggia O, Simian M, Montserrat JM, Engels JW, Iribarren AM. 2-C-methyluridine modified hammerhead ribozyme against the estrogen receptor. Bioorganic & Medicinal Chemistry Letters. 20: 2806-8. PMID 20362443 DOI: 10.1016/J.Bmcl.2010.03.060  0.655
2010 Raffo D, Pontiggia O, Sampayo R, Simian M. Abstract P4-02-11: Treatment with Fibronectin or Carcinoma Associated Fibroblast Conditioned Media Generate Sustained Tamoxifen Resistance in Breast Cancer Cells Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P4-02-11  0.766
2009 Pontiggia O, Rodriguez V, Fabris V, Raffo D, Bumaschny V, Fiszman G, de Kier Joffé EB, Simian M. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Research and Treatment. 116: 247-55. PMID 18622696 DOI: 10.1007/S10549-008-0113-3  0.797
2009 Pontiggia O, Joffé EBdK, Simian M. β1integrin mediates tamoxifen resistance in breast cancer cells. Cancer Research. 69: 1055. DOI: 10.1158/0008-5472.Sabcs-1055  0.827
2009 Pontiggia O, Raffo D, Simian M. Microenvironmental Factors Modulate Tamoxifen Resistance in Breast Cancer. Cancer Research. 69: 5133-5133. DOI: 10.1158/0008-5472.Sabcs-09-5133  0.827
2008 Casas A, Di Venosa G, Vanzulli S, Perotti C, Mamome L, Rodriguez L, Simian M, Juarranz A, Pontiggia O, Hasan T, Batlle A. Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy. Cancer Letters. 271: 342-51. PMID 18662847 DOI: 10.1016/J.Canlet.2008.06.023  0.727
Show low-probability matches.